Efficacy and Safety of Rituximab in patients with Neuromyelitis Optica Spectrum Disorders: A prospective observation in Iranian Cases.
نویسندگان
چکیده مقاله:
این مقاله چکیده ندارد
منابع مشابه
Tumefactive Brain Lesions in Patients with Neuromyelitis Optica Spectrum Disorder
Background: Neuromyelitis Optica Spectrum Disorder (NMOSD) is an autoimmune neurological disorder that is characterized by optic neuritis and longitudinally-extended transverse myelitis lesions in spinal segments. Magnetic Resonance Imaging (MRI) findings are part of the diagnostic process in NMOSD patients, and abnormal lesion patterns may cause deviation from a correct diagnosis. Clinical P...
متن کاملTreatment of neuromyelitis optica/neuromyelitis optica spectrum disorders with methotrexate
BACKGROUND To review our experience using methotrexate as a single long-term immunosuppressant (IS) therapy in neuromyelitis optica/neuromyelitis optica spectrum disorders (NMO/NMOSD). METHODS We performed a retrospective chart review of all patients with a diagnosis of NMO/NMOSD, supported by a positive NMO-IgG testing, who were treated with methotrexate. A paired sample 2 tailed t test was ...
متن کاملefficacy and safety of rituximab in neuromyelitis optica: review of evidence
neuromyelitis optica (nmo) is an autoimmune inflammatory disease of the central nervous system with preferential involvement in the optic nerve and spinal cord with a widespread spectrum of clinical features; multiple therapeutic agents have been used with different results. recent evidence points to b?cell?mediated humoral immunity in the pathogenesis of nmo. rituximab targets the cd20 antigen...
متن کاملRelationship between Azathioprine metabolites and therapeutic efficacy in Chinese patients with neuromyelitis optica spectrum disorders
BACKGROUND Neuromyelitis optica spectrum disorders (NMOSD) are demyelinating autoimmune diseases in the central nervous system (CNS) that are characterized by a high relapse rate and the presence of anti-aquaporin 4 antibodies (AQP4-IgG) in the serum. Azathioprine (AZA) is a first-line immunomodulatory drug that is widely used for the treatment of patients with NMOSD. However, the efficacy and ...
متن کاملRituximab monitoring and redosing in pediatric neuromyelitis optica spectrum disorder
OBJECTIVE To study rituximab in pediatric neuromyelitis optica (NMO)/NMO spectrum disorders (NMOSD) and the relationship between rituximab, B cell repopulation, and relapses in order to improve rituximab monitoring and redosing. METHODS Multicenter retrospective study of 16 children with NMO/NMOSD receiving ≥2 rituximab courses. According to CD19 counts, events during rituximab were categoriz...
متن کاملA 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder.
IMPORTANCE A previous 2-year analysis of repeated rituximab treatment in patients with neuromyelitis optica (NMO) revealed significant improvements in relapse rates and disability. We report the findings from the longest follow-up of rituximab treatment in NMO, which provide reassurance regarding the long-term efficacy and safety of rituximab in NMO. OBJECTIVE To report the results of rituxim...
متن کاملمنابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ذخیره در منابع من قبلا به منابع من ذحیره شده{@ msg_add @}
عنوان ژورنال
دوره 11 شماره 2
صفحات 5- 0
تاریخ انتشار 2020-03
با دنبال کردن یک ژورنال هنگامی که شماره جدید این ژورنال منتشر می شود به شما از طریق ایمیل اطلاع داده می شود.
میزبانی شده توسط پلتفرم ابری doprax.com
copyright © 2015-2023